FREMONT, Calif.--(BUSINESS WIRE)--Moximed, an innovative medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that Robert Spomer has joined the company as Senior Vice President of Sales.

加利福尼亚州弗里蒙特（商业新闻短讯）--创新医疗器械公司Moximed今天宣布，罗伯特·斯波默（RobertSpomer）加入该公司，担任销售高级副总裁。Moximed致力于提高膝关节骨性关节炎（OA）患者的护理标准。

“Robert significantly bolsters Moximed’s commercial leadership,” said Chris Gleason, President and CEO of Moximed. “He’s successfully built and led sales teams whose introduction of disruptive technologies transformed the standard of care in numerous medical fields. Moximed is rapidly investing in and expanding its commercial infrastructure, and Robert’s leadership and ability to deploy a winning formula with proven results will be instrumental as we accelerate adoption of the MISHA® Knee System.”.

Moximed总裁兼首席执行官克里斯·格里森（ChrisGleason）表示：“罗伯特（Robert）极大地巩固了Moximed的商业领导力。”。“他成功地建立并领导了销售团队，他们引入颠覆性技术改变了许多医疗领域的护理标准。Moximed正在迅速投资并扩大其商业基础设施，随着我们加速采用MISHA®膝关节系统，Robert的领导力和部署成功配方的能力将发挥重要作用。”。

Prior to joining Moximed, Spomer served as the Vice President of Sales at Intrinsic Therapeutics. Spomer previously held sales leadership roles at multiple disruptive medical technology companies, including: Stryker, Acclarent (acquired by JNJ), Spirox (acquired by Entellus), and Neotract (acquired by Teleflex)..

。斯波默之前曾在多家颠覆性医疗技术公司担任销售领导职务，包括：Stryker、Acclarent（被JNJ收购）、Spirox（被Entellus收购）和Neotract（被Teleflex收购）。。

“I am thrilled to join Moximed and help fuel the growth of the business,” said Mr. Spomer. “The MISHA Knee System has the potential to help millions of symptomatic knee OA patients regain the active and fulfilling life they deserve. The product has generated enthusiastic surgeon and patient interest, and I look forward to our team helping surgeons offer this treatment option for their patients.'.

斯波默先生说：“我很高兴加入Moximed，帮助推动业务的发展。”。“MISHA膝关节系统有可能帮助数百万有症状的膝关节OA患者恢复他们应得的积极和充实的生活。该产品引起了外科医生和患者的热情兴趣，我期待我们的团队帮助外科医生为患者提供这种治疗选择。”。

Spomer’s hire is a key role in a rapidly expanding commercial team as Moximed scales to meet increasing surgeon demand for the MISHA Knee System. Along with Spomer, recent additions include sales, reimbursement, and sales support roles as the commercial infrastructure is built out. Moximed is on pace to double full-time headcount this year..

Spomer的聘用是Moximed规模迅速扩大的商业团队中的关键角色，以满足外科医生对MISHA膝关节系统日益增长的需求。随着商业基础设施的建设，除了Spomer之外，最近还增加了销售、报销和销售支持角色。Moximed今年的全职员工人数有望翻一番。。

About The MISHA® Knee System

Moximed’s MISHA Knee System is for people with medial knee OA who failed to find relief from previous treatments. These patients continue to experience pain that interferes with daily activities, and are ineligible for, or unwilling to undergo, joint replacement due to age or absence of advanced OA..

Moximed的MISHA膝关节系统适用于膝关节内侧OA患者，这些患者未能从以前的治疗中缓解。这些患者继续经历干扰日常活动的疼痛，并且由于年龄或缺乏晚期OA而不符合或不愿意接受关节置换术。。

Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease.

。许多患有轻度至中度OA的人在他们的黄金工作年份都很健康，并且生活繁忙。对于这些患者来说，全膝关节置换术是一种不情愿的选择，因为它是终末期疾病的终末期治疗方法。

OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life..

没有终末期疾病的OA患者寻求保护膝盖，活动水平和生活质量的选择。。

Reducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA Knee System is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery.

已知减轻疼痛的骨关节炎关节的体重可以减轻疼痛并改善功能。MISHA膝关节系统是第一个植入式减震器，它可以在每一步行走时减轻膝关节的重量，减轻疼痛，保持功能，并可能延迟关节置换手术。

The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step..

植入物放置在膝盖内侧，并与自然关节一起移动，每走一步，膝盖上的峰值力就会减少约30%。。

The MISHA Knee System is FDA cleared.

MISHA膝关节系统已获得FDA批准。

About Moximed

关于Moximed

Moximed’s technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss.

Moximed的MISHA膝关节系统技术是十多年临床研究和开发的结果，是第一个用于治疗膝关节内侧骨关节炎（OA）的植入式减震器。。

Moximed is based in Fremont, California..

Moximed总部位于加利福尼亚州弗里蒙特。。

To learn more, visit www.moximed.com.

To learn more, visit www.moximed.com.